Mohammad Sabbagh, MD
Payments from drug & device makers
Across 249 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$583
- Biogen$532
- EMD Serono, Inc.$312
- AbbVie$255
- Johnson & Johnson$226
- Amgen$222
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$2025%
- Food & beverage$3,71694%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 43 | $583 |
| Biogen | 60 | $532 |
| EMD Serono, Inc. | 19 | $312 |
| AbbVie(2 entities) | 15 | $255 |
| Johnson & Johnson | 15 | $226 |
| Amgen(2 entities) | 10 | $222 |
| Sanofi | 10 | $219 |
| UCB, Inc. | 9 | $205 |
| Acorda Therapeutics, Inc | 10 | $202 |
| Supernus Pharmaceuticals, Inc. | 10 | $191 |
| Incyte Corporation | 6 | $142 |
| Teva Pharmaceuticals USA, Inc. | 6 | $105 |
| Acadia Pharmaceuticals Inc | 5 | $89 |
| Nalu Medical, Inc. | 1 | $85 |
| Pfizer | 5 | $80 |
| Lilly USA, LLC | 4 | $62 |
| Bristol Myers Squibb | 3 | $61 |
| Adamas Pharmaceuticals, Inc. | 3 | $52 |
| Eisai Inc. | 2 | $37 |
| Nevro Corp. | 1 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $24 |
| Otter Pharmaceuticals, LLC | 1 | $23 |
| Neurelis, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Cordis US CORP. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Harmony Biosciences LLC | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $13 |
How this compares
$3,935 in reported general payments places this provider in the 60th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex Pen (4 Pack)Interferon Beta-1a | 26 | $214,559 |
| Kesimpta PenOfatumumab | 23 | $198,506 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 14 | $146,630 |
| Aimovig AutoinjectorErenumab-Aooe | 139 | $123,447 |
| Nurtec OdtRimegepant Sulfate | 71 | $106,814 |
| CopaxoneGlatiramer Acetate | 12 | $81,302 |
| Teriflunomide | 20 | $75,816 |
| NuplazidPimavanserin Tartrate | 14 | $69,480 |
| Glatiramer Acetate | 13 | $33,248 |
| GlatopaGlatiramer Acetate | 14 | $30,323 |
| XcopriCenobamate | 26 | $30,157 |
| BriviactBrivaracetam | 22 | $25,232 |
| Lacosamide | 136 | $20,510 |
| FycompaPerampanel | 11 | $14,214 |
| Levetiracetam | 383 | $13,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Dilantin | $80 | $108,66284 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $105 | $81,30212 claims |
| Acadia Pharmaceuticals IncNuplazid | $89 | $69,48014 claims |
| UCB, Inc.Briviact | $205 | $25,23222 claims |
| Eisai Inc.Fycompa | $37 | $14,21411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 652 neurology providers in Michigan.
Other neurology in Flint
- Sunita TummalaFlint$378K
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.